Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARGX | ARGENX SE | $36.45B | $599.87 | $740.71 | 23.48% | Strong Buy | 14 | 973.96% | 24.89% | 38.84% | 34.43% | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.08B | $7.89 | N/A | N/A | N/A | N/A | 24.09% | 213.21% | 64.76% | 44.40% | |||
| CORT | CORCEPT THERAPEUTICS INC | $6.82B | $64.68 | $143.25 | 121.47% | Strong Buy | 4 | 28.82% | 52.97% | 116.05% | 93.82% | |||
| SRPT | SAREPTA THERAPEUTICS INC | $5.75B | $59.31 | $129.39 | 118.15% | Buy | 13 | 32.11% | 86.71% | 96.98% | 37.39% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $535.70M | $6.89 | $9.03 | 31.10% | Strong Buy | 3 | 20.03% | 35.96% | 45.54% | 30.75% | |||
| SPRY | ARS PHARMACEUTICALS INC | $1.47B | $15.00 | $28.33 | 88.89% | Strong Buy | 3 | 59.45% | 56.74% | 56.68% | 41.45% | |||
| GYRE | GYRE THERAPEUTICS INC | $808.81M | $8.64 | N/A | N/A | N/A | N/A | 49.51% | 132.23% | 428.74% | 216.48% | |||
| TGTX | TG THERAPEUTICS INC | $5.97B | $37.99 | $42.50 | 11.87% | Strong Buy | 4 | 41.33% | 151.20% | 282.55% | 108.76% | |||
| KRYS | KRYSTAL BIOTECH INC | $4.86B | $168.80 | $222.80 | 31.99% | Strong Buy | 5 | 41.48% | 61.11% | 44.73% | 40.09% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.74B | $22.60 | $33.20 | 46.90% | Strong Buy | 5 | 14.80% | 21.62% | 44.40% | 37.94% | |||
| EXEL | EXELIXIS INC | $10.21B | $36.48 | $37.81 | 3.65% | Buy | 16 | 10.51% | 22.66% | 59.24% | 45.10% | |||
| VCEL | VERICEL CORP | $1.97B | $39.42 | $61.80 | 56.77% | Strong Buy | 5 | 25.85% | 79.15% | 33.55% | 22.63% | |||
| HALO | HALOZYME THERAPEUTICS INC | $7.17B | $58.21 | $64.67 | 11.09% | Buy | 6 | 19.11% | 28.50% | 297.54% | 52.46% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.67B | $29.18 | $56.00 | 91.91% | Strong Buy | 6 | 17.47% | 25.64% | 55.91% | 36.88% | |||
| RIGL | RIGEL PHARMACEUTICALS INC | $316.89M | $17.74 | $36.80 | 107.44% | Buy | 5 | 12.31% | 31.54% | 1,733.05% | 34.75% | |||
| RPRX | ROYALTY PHARMA PLC | $18.56B | $32.19 | $40.00 | 24.26% | Strong Buy | 1 | 19.38% | 62.05% | 30.52% | 17.32% | |||
| NVO | NOVO NORDISK A S | $267.50B | $59.91 | $112.00 | 86.95% | Buy | 2 | 15.61% | 18.52% | 127.89% | 39.40% | |||
| INCY | INCYTE CORP | $11.10B | $57.38 | $74.36 | 29.59% | Hold | 14 | 9.75% | 264.00% | 50.55% | 32.01% | |||
| ADMA | ADMA BIOLOGICS INC | $5.08B | $21.39 | $25.33 | 18.43% | Strong Buy | 3 | 20.25% | 10.07% | 98.04% | 70.02% | |||
| MNKD | MANNKIND CORP | $1.39B | $4.58 | $9.50 | 107.42% | Strong Buy | 2 | 15.08% | 46.28% | -173.34% | 34.69% | |||
| MDXG | MIMEDX GROUP INC | $984.41M | $6.68 | $13.00 | 94.61% | Strong Buy | 1 | 12.33% | 33.56% | N/A | N/A | |||
| VCYT | VERACYTE INC | $2.43B | $31.13 | $42.00 | 34.92% | Buy | 8 | 10.27% | 72.13% | 7.69% | 6.95% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.73B | $61.50 | $93.85 | 52.60% | Buy | 13 | 10.05% | 32.28% | N/A | N/A | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $6.28B | $103.38 | $188.67 | 82.50% | Strong Buy | 12 | 5.55% | 31.52% | N/A | N/A | |||
| TECH | BIO-TECHNE CORP | $7.76B | $49.08 | $78.83 | 60.62% | Buy | 6 | 6.11% | 39.71% | N/A | N/A | |||
| ACAD | ACADIA PHARMACEUTICALS INC | $2.39B | $14.35 | $24.17 | 68.41% | Buy | 6 | 10.44% | 4.70% | 50.55% | 31.19% | |||
| GMAB | GENMAB A | $13.42B | $20.27 | $39.25 | 93.64% | Strong Buy | 4 | 18.28% | 12.73% | 4.49% | 3.60% | |||
| UTHR | UNITED THERAPEUTICS CORP | $13.15B | $292.82 | $401.88 | 37.24% | Strong Buy | 8 | 6.19% | 2.04% | 23.91% | 20.92% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $64.01B | $585.49 | $950.30 | 62.31% | Buy | 20 | 5.70% | 2.09% | 22.23% | 17.28% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.